Loading clinical trials...
Loading clinical trials...
Rationale: Primary hyperaldosteronism (PA) is the most frequent and possibly curable form of secondary hypertension. The diagnosis and targeted treatment of PA is essential because of high vascular mo...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Helsinki University Central Hospital
Collaborators
NCT05797558 · Primary Hyperaldosteronism Due to Adrenal Adenoma
NCT03474237 · Adrenal Adenoma, Cushing Syndrome, and more
NCT04251780 · Primary Hyperaldosteronism, Electrolyte Disturbance
NCT03405025 · Primary Hyperaldosteronism, Primary Hyperaldosteronism Due to Adrenal Adenoma
NCT00732771 · Primary Hyperaldosteronism
Helsinki University Central Hospital
Helsinki
Tampere University
Tampere
University of Turku
Turku
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions